Whether PARP1–SIRT1 imbalance occurs in human Chagas disease and whether PARP1 inhibitors or SIRT1 agonists will be useful in improving the cardiac outcomes in human Chagas disease remain to be investigated in future studies. Here, PARP1 is linked to Chagas disease.